These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 33260353)

  • 1. Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance.
    Ellsworth M; Ostrosky-Zeichner L
    J Fungi (Basel); 2020 Nov; 6(4):. PubMed ID: 33260353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
    Rybak JM; Marx KR; Nishimoto AT; Rogers PD
    Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
    Miceli MH; Kauffman CA
    Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
    Pettit NN; Carver PL
    Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of isavuconazole in the treatment of invasive fungal infections.
    Wilson DT; Dimondi VP; Johnson SW; Jones TM; Drew RH
    Ther Clin Risk Manag; 2016; 12():1197-206. PubMed ID: 27536124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
    Ledoux MP; Denis J; Nivoix Y; Herbrecht R
    J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
    Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
    Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations.
    Natesan SK; Chandrasekar PH
    Infect Drug Resist; 2016; 9():291-300. PubMed ID: 27994475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Perspectives on Antimicrobial Agents: Isavuconazole.
    Lewis JS; Wiederhold NP; Hakki M; Thompson GR
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0017722. PubMed ID: 35969068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.
    Falci DR; Pasqualotto AC
    Infect Drug Resist; 2013 Oct; 6():163-74. PubMed ID: 24187505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections.
    Donnelley MA; Zhu ES; Thompson GR
    Infect Drug Resist; 2016; 9():79-86. PubMed ID: 27330318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
    McCarthy MW; Moriyama B; Petraitiene R; Walsh TJ; Petraitis V
    Clin Pharmacokinet; 2018 Dec; 57(12):1483-1491. PubMed ID: 29725999
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Pfaller MA; Rhomberg PR; Wiederhold NP; Gibas C; Sanders C; Fan H; Mele J; Kovanda LL; Castanheira M
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole.
    Thompson GR; Chen SC; Alfouzan WA; Izumikawa K; Colombo AL; Maertens J
    Med Mycol; 2024 Sep; 62(9):. PubMed ID: 39138063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isavuconazonium sulfate for the treatment of fungal infection.
    Walker RC; Zeuli JD; Temesgen Z
    Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.
    Chitasombat MN; Kontoyiannis DP
    Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
    Livermore J; Hope W
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
    Shirley M; Scott LJ
    Drugs; 2016 Nov; 76(17):1647-1657. PubMed ID: 27766566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.